Foamix develops topical dermatology drugs and is known for an antibiotic foam product. The company is awaiting a delayed FDA decision on its topical dermatology candidate, with approval described as being "in sight." In anticipation of that regulatory milestone, Foamix returned to its largest shareholders for funding. Major investors Perceptive and OrbiMed committed $64 million to the company. The raise was positioned around the upcoming FDA date and potential commercialization of the antibiotic foam. The article does not provide operating metrics or additional financial terms beyond the $64M commitment.

Total raised

$64M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2019